Andrea Lobo, Science Writer —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

$132.5M raised to advance ENV-101’s clinical development for IPF

Endeavor BioMedicines has raised $132.5 million toward the clinical development of its pipeline programs, including ENV-101, an investigational oral treatment for idiopathic pulmonary fibrosis (IPF). Results from a recent Phase 2a trial (NCT04968574) showed ENV-101 was generally well tolerated, reduced tissue scarring, or fibrosis, and improved lung…

Enrollment complete for Phase 2b trial testing LYT-100 in IPF patients

Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The trial, called ELEVATE IPF (NCT05321420), is assessing the safety, efficacy, and dosing regimen of LYT-100 in 240 adults with IPF, compared with a placebo.

BMS-986278 declared breakthrough therapy for progressive PF

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF). Breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening diseases. The decision is based on preliminary…

FDA approves new Esbriet generic from Lupin for IPF

The U.S. Food and Drug Administration (FDA) has approved a new generic version of Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF), according to an announcement by Lupin, the global pharmaceutical company that will market the medication. As with the brand name medicine, Lupin‘s generic will be available…

Shorter telomeres, protective caps for DNA, may raise IPF risk

People with shorter telomeres, or chromosome “caps,” may be at a greater risk of developing idiopathic pulmonary fibrosis (IPF), a study reported. This work “also provided some interesting genetic evidence to prove that obesity and exposure to tobacco smoking as a fetus might also contribute to the development of…

First IPF patient dosed in Phase 2 trial of bersiporocin

The first patient has been dosed in a Phase 2 clinical trial of bersiporocin, Daewoong Pharmaceutical’s treatment candidate for idiopathic pulmonary fibrosis (IPF). Full patient dosing and initial data from the study are anticipated by 2024, according to Daewoong. “Daewoong Pharmaceutical has set the significant first step to the…

IPF Treatment RXC007 Shows Promise in Easing Scarring in Mice

The treatment candidate RXC007 demonstrated promising efficacy in easing fibrosis, or scarring, in mouse models of idiopathic pulmonary fibrosis (IPF) and other scarring-related conditions. In healthy human volunteers participating in a recently-completed Phase 1 trial, RXC007 displayed a good safety and pharmacological profile. Now, Redx Pharma, the company…